Skip to content

NeoMega36®: Neobiomics’ Journey to Bridging Unmet Needs

In the dynamic world of healthcare, identifying unmet needs and swiftly addressing them is our motto. In the past year, we have successfully identified and bridged a gap in neonatal nutrition. The result? NeoMega36®! 

From the outset, we have embraced a data-driven approach to product development. We have relied on scientific data that has helped us meticulously craft NeoMega36®. Our team refined and adapted the product to cater specifically to the needs of neonatal nutrition. In parallel, we also engaged in a continuous dialogue with the neonatal staff network, forming a tight-knit community that provided us with valuable feedback.

Philipp Novak, the co-founder of Neobiomics, emphasized our stance in this journey and quoted: “By the community, for the community.” 

This ethos underscores our collaborative efforts with neonatal professionals and our partners, ensuring that our product aligns seamlessly with the evolving needs of healthcare providers and patients.

Understanding the nutritional requirements we began our journey by partnering with 4LifeScience, a Munich-based lab. That crafted the right methods for performing filling, chemical analyses, stability studies, and microbiological tests. Our partners at 4LifeScience have designed a specific filling process that not only adapts to technological advancements but also enhances our product’s stability and overall quality.

Addressing the regulatory requirements, we notified the product as a Food Supplement for Medical purposes (FSMP). Preterm infants may develop a deficiency of important essential polyunsaturated fatty acids arachidonic acid (ARA) and docosahexaenoic acid (DHA). This can contribute to abnormal development of eye function, as demonstrated by two Nordic research projects*. 

Neomega36® is a vegan formulation and contains the same balanced mixture of ARA and DHA as present in breast milk in the ratio of 2:1. The application and administration of Neomega36® is streamlined for ease while fulfilling the nutritional requirements. 

It is currently available in the Nordics and Germany, and we hope NeoMega36® continues to make waves in neonatal nutrition also in other countries.

For more information, kindly feel free to reach us at  

*1. Hellström et al JAMA Pediatr 2021 175 359 367 https :://doi org/ 10 1001 /jamapediatrics 2020 5653
2.  Wendel et al Clin Nutr 2023 Jan 42 1 22 28 https :://doi org/ 10 1016 /j clnu 2022 11 012